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ABSTRACT
Unlike deﬁnition of stroke and myocardial infarction, there is no
uniformly agreed upon deﬁnition to adjudicate end-stage renal
disease (ESRD). ESRD remains the most unambiguous and clin-
ically relevant end point for clinical trialists, regulators, payers
and patients with chronic kidney disease. The prescription of dia-
lysis to patients with advanced chronic kidney disease is subject-
ive and great variations exist among physicians and countries.
Given the difﬁculties in diagnosing ESRD, the presence of esti-
mated GFR <15 mL/min/1.7 3m2 itself has been suggested as
an end point. However, this deﬁnition is still a surrogate since
many patients may live years without being symptomatic or
needing dialysis. The purpose of this report is to describe a
framework to deﬁne when the kidney function ends and when
ESRD can be adjudicated. Discussed in this report are (i) the im-
portance of diagnosing symptomatic uremia or advanced asymp-
tomatic uremia thus establishing the need for dialysis; (ii)
establishing the chronicity of dialysis so as to distinguish it
from acute dialysis; (iii) establishing ESRD when dialysis is un-
available, refused or considered futile and (iv) the adjudication
process. Several challenges and ambiguities that emerge in clin-
ical trials and their possible solutions are provided. The criteria
proposed herein may help to standardize the deﬁnition of ESRD
and reduce the variability in adjudicating the most important
renal end point in clinical trials of chronic kidney disease.
Keywords: adjudication, clinical trials, death, end point,
end-stage renal disease
INTRODUCTION
Worldwide, end-stage renal disease (ESRD) has produced a
burden that is both social and economic. However, until now,
the number of large successful clinical trials that have shown to
delay the onset of ESRD has been three [1–3]. And all three con-
ducted among patients with diabetic nephropathy have found
that blockade of the renin angiotensin systemmitigates the pro-
gression to ESRD [1–3]. Although each of these three trials used
a composite end point of doubling of serum creatinine, ESRD
or death to seek regulatory approval for delaying kidney failure,
the only ﬁrm and unambiguous end point that represents irre-
versible kidney failure is ESRD; this end point was met in only
two of the three trials [1, 2]. ESRD is a clinically meaningful end
point that affects both well-being and lifespan. However, com-
pared with end points such as stroke, myocardial infarction or
death, ESRD is an end point that is more subjective in nature.
Unlike, the clear guidelines that exist which deﬁne myocardial
infarction [4] and stroke [5], at this time there are no universally
accepted deﬁnitions of ESRD. The lack of a universal deﬁnition
poses a challenge in developing effective therapies.
Drawing from personal experience in adjudicating ESRD in
multicenter, randomized trials, the purpose of this report is to
describe a framework to deﬁne when the kidney function ends
and when ESRD can be adjudicated.
THE NEED FOR DEFINING ESRD
Although several trials have deﬁned ESRD, the deﬁnitions are
limited. The published deﬁnitions from prior trials each of
which had progression of CKD to ESRD as a primary or sec-
ondary end point are as follows:
(i) The reduction of end points inNIDDMwith the Angioten-
sin II Antagonist Losartan (RENAAL) study deﬁned ESRD
as the need for long-term dialysis or transplantation [2].
(ii) Irbesartan diabetic nephropathy trial (IDNT) deﬁned
ESRD as the initiation of dialysis, renal transplantation
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or a serum creatinine concentration of at least 6.0 mg/dL
(530 μmol/L) [3].
(iii) Study of Heart and Renal Protection (SHARP) trial de-
ﬁned it as the need for long-term dialysis or transplant-
ation [6].
(iv) The Trial to Reduce Cardiovascular Events with Aranesp
Therapy (TREAT) deﬁned ESRD as decrement in the
subject’s kidney function to a level at which either dialysis
or kidney transplantation is required to sustain life meet-
ing one of the following: (i) underwent >30 days of dia-
lysis therapy, (ii) received a kidney transplant, (iii) a
physician recommended renal replacement therapy
(RRT) (dialysis and/or transplant) and the subject re-
fused therapy or (iv) began dialysis and expired <30
days later [7].
A FRAMEWORK FOR DEFINING ESRD
To deﬁne ESRD, two criteria must be fulﬁlled: establishing the
presence of uremia and the need for RRT which is chronic.
Although there are many controversies on what may constitute
ESRD (Table 1), discussed further below is what constitutes ur-
emia that may be either symptomatic or asymptomatic and
what may be reasonably and practically deﬁned as chronic RRT.
Symptomatic uremia
As CKD progresses to ESRD, patients frequently present
with characteristic signs and symptoms, due to worsening
uremia. Once these signs and symptoms develop, RRT whether
it be renal transplantation, peritoneal dialysis or hemodialysis is
necessary to reverse the symptoms of uremia and prolong life.
The challenge is that in the vast majority of the patients, the
signs and symptoms of uremia are nonspeciﬁc and variable.
The interpretation of these signs and symptoms being attribut-
able to uremia, at least in the early stages, is subjective. For
example, signs and symptoms of nausea, vomiting, deterioration
in nutritional status, recent signiﬁcant weight loss and fatigue
could be due to diabetic gastroparesis or could be attributed
to uremia. Similarly, neurologic dysfunction (e.g. neuropathy,
encephalopathy, psychiatric disturbances, seizures), bleeding
diathesis, pleuritis, pericarditis, intractable sleep disturbance,
anhedonia or diuretic refractory volume overload (manifested
as shortness of breath, effort intolerance, severe edema) may
be attributed to uremia or other causes.
Some patients may be asymptomatic, nonetheless may have
indications for initiation of chronic dialysis such as due to
hypertension poorly controlled with multiple drugs or hyper-
kalemia unresponsive to reasonable medical management.
It is important to note that no diagnostic criteria exist to
establish the presence of symptomatic uremia. Often, but not
always, worsening of symptoms together with deterioration of
kidney function is used to establish that uremia is symptomatic.
Ultimately, it is the experienced physician who can best estab-
lish the presence of the uremic syndrome at the bedside. Thus,
documented reasoning of the physician, whomakes the diagno-
sis of the uremic syndrome, can provide invaluable support
when ascertaining the presence of symptomatic uremia. This
is particularly important in multicenter trials where despite ac-
cess to raw data it may be difﬁcult to establish the presence of
symptomatic uremia for the adjudicators.
Advanced asymptomatic uremia
The above deﬁnitions may not diagnose all ESRD. Some
patients may remain asymptomatic and without hyperkalemia
or poorly controlled hypertension despite a very low eGFR. Al-
though it is possible that patients with extremely low eGFR
may be asymptomatic, it is to be noted that many require dia-
lysis initiation. For example, the initiating dialysis early and late
study tested the effect of wait-and-watch approach (delayed
start) prior to initiating dialysis compared with an early start
[8]. The intent was to initiate RRT early when estimated GFR
was between 10 and 14 mL/min and to test this strategy against
a late-start when GFR was between 5 and 7 mL/min for hard
outcomes on follow-up. In the usual group, only 18.6% of the
patients started dialysis when eGFR was <10 mL/min/1.73 m2.
On the other hand, in the late-start group, 75.9% of the patients
were dialyzed at estimated GFR of >7 mL/min/1.73 m2. This
provides the rationale for a threshold of <8 mL/min/1.73 m2
to be a permissible estimated GFR at which an experienced clin-
ician may weigh the beneﬁts of initiating dialysis to outweigh its
risks. Accordingly, when the physician believes that the beneﬁt
of RRT exceeds the risks of waiting for symptoms to develop
when eGFR has dropped to <8 mL/min/1.73 m2 and patient
undergoes chronic dialysis such cases can be adjudicated as
ESRD.
Considerations for establishing chronicity
Patients may have a transient acute decline in kidney func-
tion that may recover with a few dialysis treatments. Thus, to
diagnose ESRD unambiguously, chronicity needs to be estab-
lished. The duration of RRT can be useful to establish chron-
icity. Whether 30, 60 or 90 days is sufﬁcient to establish
ESRD can be debated. Shortening the duration requirement
will trade speciﬁcity for sensitivity. Prolonging the duration
to say 90 days may cause needless delay in time to adjudicating
ESRD events. Accordingly, to provide a compromise, I suggest
that the patient should undergo regular course of dialysis over at
least 30 days. Furthermore, there should be absence of evidence
that the patient recovered from dialysis over 3 months.
Table 1. Examples of uncertainties in the diagnosis of ESRD
1 Is it rational to distinguish symptomatic from asymptomatic uremia?
2 In an asymptomatic patient what should be the threshold of eGFR that
may be considered acceptable to initiate dialysis in the absence of
symptoms?
3 For how many days should the patient receive dialysis before it is
considered chronic?
4 Should the patient with CKD who requires dialysis for AKI who then
dies be counted as ESRD?
5 Should an eGFR of <15 mL/min/1.73 m2 be used as a hard end point in
clinical trials?
6 If the dialysis is deemed futile, should the date on which such a
discussion occurred or when death occurred be taken as the date of
event?
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When a regular course of dialysis has not been documented
for 30 days or more, questions may arise regarding whether the
event was chronic in nature. If a patient is unable to continue for
30 or more days after initiating chronic dialysis due to receiving
a renal transplant or the patient dying, the event can be classiﬁed as
ESRD, and the datewhen dialysis was initiated considered the date
of the ESRD event. The cause of death (cardiovascular or not)
should also be adjudicated.
Establishing ESRD when dialysis is not delivered
Patients may refuse RRT because they believe that their cur-
rent quality of life, with their expected lifespan, outweighs the
quality and quantity of life following RRT. It may also occur
when the clinician withholds RRT and the patient consents be-
cause both the clinician and the patient consider RRT futile and
they believe that the patient’s current quality of life, with their
expected lifespan, outweighs the quality and quantity of life fol-
lowing RRT. In some instances, the clinicianmaywithhold RRT
without the patients consent. Occasionally, RRT is planned and
the speciﬁc start date is documented but the patient dies prior to
starting dialysis. Rarely, RRT may not be available or be afford-
able by the patient. In such instances, the date they need for
dialysis is established and it is considered the date of ESRD. If
such a patient dies, the cause of death would be separately
adjudicated.
Acute kidney injury in CKD precipitating the need
for dialysis
The progression to ESRD may not be an inexorable chronic
decline in kidney function. An acute illness (e.g. pneumonia) or
surgery may trigger an acute deterioration in kidney function
warranting dialysis. The physician may decide in the context
of advanced kidney failure and severity of injury that there is
little possibility that the patient will recover substantial kidney
function to sustain life without RRT. If RRT is initiated and the
patient dies within 30 days of initiation of dialysis, such a
patient should be counted as ESRD. The context is important;
adjudication committees can sometimes need to weigh in if the
patient had ESRD or not. For example, if the patient has septic
shock and AKI requiring dialysis and dies within a few days of
initiating RRT, should this be considered ESRD? If the patient
had little or no evidence of CKD, the committee may decide it is
not ESRD. On the other hand, if Stage 4 CKD was present,
superimposed AKI needing dialysis may be considered ESRD.
This is because few people with advanced CKD and AKI will
recover completely to come off dialysis. After an AKI event
which leads to dialysis, it is difﬁcult to predict renal recovery
had the patient survived. AKI events accelerate the progression
to ESRD and had the patient survived, it is possible that the
length of time to dialysis would have been shortened. Thus,
in a trial where all participants have CKD, it is my view that
AKI events leading to dialysis and death while being on dialysis
be counted as an ESRD event.
Renal transplantation
Renal transplantationmay occur at any time due to the avail-
ability of a transplant and the health of the patient. Therefore,
the date of transplantation even if the patient does not survive
the surgical procedure should be considered conﬁrmation of the
onset of ESRD.
Identiﬁcation of events
Large clinical trials often have physicians other than ne-
phrologists who participate as investigators. For example, inter-
nists and endocrinologists may participate in a diabetic
nephropathy trial. Often the principal investigator is not the
physician treating the patient who may be hospitalized. Thus,
the detection of ESRD events is not trivial. Education of the
investigator regarding the need for detecting symptomatic ur-
emia, the concept of eGFR and RRT is therefore important.
Especially important is the need to identify the need for RRT
in the hospital. To err on the side of safety, any dialysis treat-
ment should trigger the need for committee review. The
ESRD events are ideally identiﬁed by the investigators and re-
ported as such. However, ESRD events may be identiﬁed by
sponsors by reviewing the adverse event forms and discharge
summaries, and by standardized medical queries of the data-
base. Especially important may be reports by the pharmacovigi-
lance group of the sponsoring company.
The adjudication process
In a blinded way, and without the knowledge of drug group
assignment, at least two experienced nephrologists should re-
view and vote on a case with ESRD. In instances when the two
nephrologists disagree, a third nephrologist, without knowledge
of the ﬁrst two votes, should evaluate the case as well. If all three
members disagree (say on the date of event) a panel meeting
with help of a chairperson can resolve the differences.
DISCUSSION
Progressive symptoms of uremia together with decline in kid-
ney function often trigger the onset of dialysis and thus herald
the onset of ESRD. The syndrome of symptomatic uremia is dif-
ﬁcult to deﬁne but easy to recognize at the bedside. No single
sign or symptom or even a cluster of symptoms listed can ﬁrmly
establish the diagnosis of uremia. Thus, a narrative by the treat-
ing physician outlining the rationale why the patient has symp-
tomatic uremia and needs initiation of RRT may be invaluable
in adjudicating the presence of symptomatic uremia. By requir-
ing the need for dialysis for at least 30 days, not known to sub-
sequently recover (for at least 90 days), the question of
reversibility of decline in kidney function is mitigated and the
diagnosis of ESRD is established. However, as noted above,
there are several situations where ESRDmay be diagnosed with-
out the patient having symptomatic uremia or needing chronic
dialysis. Examples of such situations are extremely low GFR,
renal transplantation, or death shortly after initiating dialysis.
In the latter case, dialysis is required to be initiated for the intent
of treating chronic uremia; those who had no prior CKD may
not qualify for the diagnosis of ESRD.
Should Stage 5 CKD be called ESRD?
Given the difﬁculties in diagnosing ESRD, one may propose
that the presence of estimated GFR <15 mL/min/1.73 m2 itself
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should constitute an end point. Despite being simple to adjudi-
cate, there are several reasons against this deﬁnition. First, many
patients remain asymptomatic of uremia for long periods of
time despite having this arbitrarily low estimated GFR; thus,
this end point is not clinically meaningful to these patients.
Second, drugs (e.g. cimetidine) may alter serum creatinine con-
centration independent of GFR, and inﬂuence this end point.
Third, the economic impact of such an end point instead of pro-
vision of dialysis is difﬁcult to measure; the economic impact
would be important for payers. Thus, this end point remains
a surrogate of ESRD.
Should provision of RRT alone serve as an end point?
Since the provision of dialysis itself is such a clinically mean-
ingful end point, the requirement to establish the need for RRT
may be questioned. Despite the subjective nature of decision to
initiate dialysis, the provision of dialysis is a landmark event and
changes the quality of life of the patient and costs to the society.
In this context, the provision of long-term dialysis itself may be
considered as an appropriate end point. Past experience sug-
gests that substantial differences exist among physicians and
countries on what is considered appropriate symptoms for es-
tablishing uremia. Waiting to initiate dialysis before symptoms
of uremia are manifest is associated with a survival that is simi-
lar to an earlier start of dialysis. In a clinical trial, to ensure that
the ESRD outcomes in the treated and control groups were direc-
tionally similar regardless of reason why dialysis was initiated due
to symptomatic and asymptomatic uremiawould be important to
the scientiﬁc community, the regulators and the payers.
Challenges in establishing chronicity
Establishing chronicity may seem trivial but can pose to be
challenging in clinical trials. Once the trial participant initiates
dialysis, he or she may stop study medication and have less
interaction with the trial site. Many trials follow patients for
at least 30 days after stopping the study drug. Since study
drug is often stopped with the onset of dialysis, establishing
whether the patient is on regular RRT and remains on dialysis
30 days after initiation is less burdensome. Communication
such as through a phone call or a letter with the study partici-
pant establishing that the kidney function has not recovered at
90 days is important because it will further establish chronicity.
Acute kidney injury and dialysis
All dialysis is not ESRD. For example, acute kidney injury
may result in sudden, large and potentially reversible declines
in renal function. The treating physician may initiate dialysis
to treat drug overdose. Dialysis may be performed to treat vol-
ume overload, severe hyperkalemia or severe acidosis with an
intention to relieve that acute complication of sudden decline
in kidney function. This may be the case when the baseline
level of kidney function is excellent and decline in kidney func-
tion is large. The physician may reasonably believe that such a
decline in kidney function is reversible. If the intention of the
dialyzing physician is to provide relief to the acute manifest-
ation of uremia and not provide chronic RRT, then the date
of initiation of RRT cannot be considered the date of onset of
ESRD. However, if such a patient dies of cardiovascular causes
he would contribute to the composite end point on the date of
cardiovascular death. On the other hand, if at baseline the level
of kidney function is severely impaired and the acute injury is
severe, the physician may reasonably believe that dialysis may
be needed for the long term. The intention of the physician is
to initiate chronic dialysis. If the patient does not recover sufﬁ-
cient renal function and remains on chronic dialysis for at least
30 days then chronicity is established and the date of initiation
of dialysis is considered to be the date of ESRD. This is despite
dialysis being initiated for an acute decline in kidney function.
In conclusion, a framework for deﬁnition for adjudicating
ESRD events primarily for use in clinical trials for regulatory
purposes is provided. Careful adjudication of this end point is
superior to accepting a surrogate deﬁnition of ESRD as eGFR
<15 mL/min/1.73 m2. Several challenges to the diagnosis of
ESRD such as establishing the presence of symptomatic uremia,
variations in the practice of initiating dialysis, and ascertaining
ESRD in the absence of dialysis are noted. However, the criteria
proposed herein may help to standardize the deﬁnition of
ESRD and reduce the variability in adjudicating the most im-
portant renal end point which is of great relevance to patients,
their providers, regulators and payers.
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